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Naringin (NAR) and naringenin (NGE) are flavonoids with important effects, such as antioxidant, nephroprotective and 
anti-inflammatory action. However, factors such as poor solubility and oral bioavailability, gastrointestinal instability and 
extensive first pass metabolism lead to limited deliverability. As far as we know, there are no papers describing the use of 
combination of NAR and NGE in nanoparticles. This paper describes the development and characterization of novel 
nanoparticles containing NAR and NGE (NAR-NGE-NPs) which were prepared by nanoprecipitation using ethanol. Size 
distribution of NAR-NGE-NPs demonstrated a narrow distribution (121 nm), low polydispersity (< 0.1), and encapsulation 
efficiencies were greater than 80%. Infrared spectroscopy analyses confirmed the structure of NAR-NGE-NPs and in 
transmission electron microscopy, NAR-NGE-NPs presented a spherical and regular shape. A degradation study by UV-
C, NAR-NGE-NPs improved photostability and conferred protection against NAR and NGE degradation. Minimal 
inhibitory concentrations of NAR and NGE were evaluated, however samples did not show antimicrobial activity. In this 
investigation, new NAR-NGE-NPs were successfully developed by a nanoprecipitation technique, using Endragit® L100 
as polymer and ethanol as solvent. 
 






In genus Citrus, some plants have not yet been much 
studied, as in the case of grapefruit (Citrus maxima). The 
main flavonoids of grapefruit are naringin (NAR) and its 
aglycone, naringenin (NGE) [1]. NAR and NGE exert a 
variety of biological/pharmacological effects such as 
antioxidant, antiatherogenic, hepatoprotective, 
nephroprotective and anti-inflammatory [2-4]. In two 
studies with rats applying streptozotocin induced 
diabetes, NAR was able to avoid diabetic neurogenic pain 
by preventing free radical formation and antioxidant 
activity in the sciatic nerve [5]. In addition, NGE 
decreased the blood glucose level and improved 
dyslipidemia [6]. In another study, the treatment of mice 
for six months with NGE led to a reduction in the 
progression of atherosclerosis [7]. In rabbits fed with a 
high cholesterol diet, supplementation of 0.1% NAR or 
0.05% of NGE for eight weeks decreased aortic fatty 
streak area when compared to controls [8]. However, the 
deliverability of NAR and NGE is limited due to its poor 
aqueous solubility, gastrointestinal instability, extensive 
first pass metabolism and poor oral bioavailability [9]. 
Evidence was provided that orally administered NAR was 
hydrolyzed by enterobacteria to aglycone before 
absorption and NGE have a rapid distribution and 
elimination [10]. In such cases, polymeric nanoparticles 
(NPs) probably minimize these problems, modifying drug 
delivery profiles, improving stability, increasing 
solubility and protecting drug against fast metabolism  
[11]. It is essential to select the polymer appropriately in 
order to develop successful polymeric NPs. Therefore, 
methacrylic acid copolymers have been extensively 
studied, such as Eudragit® L100, resulting from the 
anionic copolymerization of methacrylic acid and methyl 
methacrylate, with pH-dependent behavior [12-13]. 
In the present study, we describe the preparation and 
extensive optimization of naringin-naringenin-
nanoparticles (NAR-NGE-NPs) with different solvents. 
As far as we know, there are no papers describing the 
combination of NAR and NGE in NPs. The best 
formulation was characterized in terms of morphology, 
chemical composition and crystallinity, the 
photodegradation kinetics and stability studies of NAR-
NGE-NPs were performed. Antibacterial assay by 
minimal inhibitory concentration (MIC) of NAR and 
NGE was also assessed. 
 




NAR with 96.6% purity, NGE with 99.2% purity and 
sorbitan monostearate were purchased from Sigma-
Aldrich® (Buchs, Switzerland). Eudragit® L100 and 
Eudragit® S100 (Methacrylic Acid - Methyl 
Methacrylate Copolymer) were supplied by Röhm 
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Pharma Polymers® (Dramstadt, Germany). Polysorbate 
80 and isopropyl adipate were purchased from Via 
Farma®. All solvents were of analytical grade and 
obtained from various sources and MilliQ® water was 
used throughout the experiment. 
 
Preparation and optimization of nanoparticles 
containing naringin and naringenin 
 
The NPs were prepared according to the method of 
interfacial deposition of pre-formed polymer 
(nanoprecipitation) described by Fessi and collaborators 
with modifications [14]. The organic phase containing the 
two flavonoids (0.05 g of each), Eudragit® L100 or 
Eudragit® S100 (0.25 g), sorbitan monostearate (0.0962 
g), isopropyl adipate (0.395 g) dissolved in ethanol or 
mixture of solvents (qsp 100 mL) (isopropanol, 
tetrahydrofuran, acetone) were poured over the aqueous 
phase containing polysorbate 80 (0.385 g). The organic 
solvent was removed, evaporated until a final volume of 
25 mL and the suspension was stored at room temperature 
(25 ± 3 ºC). NAR and NGE-free NPs were prepared 
following the same procedure as for NAR-NGE-NPs. The 
preparation of NAR-NGE-NPs was optimized to obtain a 
final formulation with adequate macroscopic analysis, 
small particle size (<200 nm), low polydispersity index 
(PdI <0.2) and large zeta-potential.  
 
Characterization of nanoparticles  
 
Determination of the particle size, polydispersity index 
and zeta-potential 
 
The determination of particle size and polydispersity 
index (PdI) of the NAR-NGE-NPs was performed in 
triplicate by dynamic light scattering (Zetasizer®, model 
ZEN 3600, Malvern) after 500-fold dilution (v/v) in 
water. The zeta-potential was obtained by electrophoresis 
(Zetasizer®, model ZEN 3600, Malvern), after 500-fold 
dilution (v/v) in NaCl 10 mM. 
 
Determination of naringin and naringenin concentration 
and encapsulation efficiencies 
 
The concentration and encapsulation efficiencies were 
determined using the stability-indicating high-pressure 
liquid chromatography (HPLC) method, previously 
validated as described by Cordenonsi and co-workers 
[15]. Successful resolution and retention times were 
obtained with a Zorbax Eclipse Plus C18 column (4.6 mm 
x 150 mm, 5 µm) at a temperature of 25 °C, at a 1 mL 
min-1 flow rate, 285 nm wavelength and the injection 
volume was 20 µl. Ultrapure water (A) with pH 4.0, 
adjusted with hydrochloric acid 0.1 M and acetonitrile (B) 
were used to prepare the mobile phase. Separation was 
performed using gradient elution: 0-4 min 10%-70% B 4-
5 min 70-100% B 5-6 min 100-70% B 6-8 min 70-10% B. 
At the interval between each run, the system remained 
under a stabilization process for three minutes. The stock 
solution was prepared with ethanol and the dilutions were 
done with water at pH 4.0 and acetonitrile (1:1) (v/v). The 
method was linear in the range of 1.0–40.0 µg mL-1 for 
both NAR and NGE (r> 0.99) with adequate results for 
precision (<0.9%) and accuracy (98.8%). Limits of 
detection and quantification were 0.11; 0.38 μg mL-1 and 
0.35; 0.90 μg mL-1 for NAR and NGE, respectively. The 
specificity of the method and its stability indicating 
capability were demonstrated through forced degradation 
studies, which showed that there was no interference from 
the excipients. The Plackett-Burman experimental design 
was used to evaluate robustness producing results within 
the acceptable range. 
NAR and NGE were determined in the ultrafiltrate after 
separation of the NAR-NGE-NPs suspension by 
ultrafiltration–centrifugation technique. The total content 
of NAR and NGE in the suspension was determined using 
HPLC after dissolution in acetonitrile. The associated 
NAR and NGE with the NPs suspension were calculated 
from the difference between the total and the free drug 
concentrations determined in the NPs suspension and in 
the ultrafiltrate, respectively. The HPLC (Agilent® 1200 
series, Santa Clara, USA) was equipped with a quaternary 
pump, auto-injector, compartment with thermostat, 




The viscosity of NAR-NGE-NPs suspension was 
measured at 25 ± 1 °C using a rotational viscometer 
(LVDV II+ Pro model, Brookfield, USA) equipped with 
SC4-25 spindle and a small sample adapter. 
 
Transmission electron microscopy 
 
Surface morphology of NAR-NGE-NPs and control-NPs 
were evaluated by transmission electron microscopy 
(TEM) (JEM 1200EX II) operated at 120 kV. For this 
analysis, the diluted suspensions with water (1:10) were 
deposited on a specimen grid (Formvar-Carbon support 
film, Electron Microscopy Sciences) and stained with 




The molecular characteristics of NAR, NGE, NAR-NGE-
NPs and Eudragit® L100 were subjected to infrared 
spectra (IR), on Shimadzu® (model 8001). The spectra 
were obtained via the Attenuated Total Reflection (ATR) 
method in a frequency range of 4,000–600 cm-1.  
 
Differential scanning calorimetry 
 
The physical state of NAR, NGE, NAR-NGE-NPs and 
control-NPs was analyzed using a differential scanning 
calorimeter (DSC) Shimadzu (Shimadzu, Kyoto, Japan), 
model DSC-60, with flow controller FC-60, integrator 60 
WS and software TA 60 (version 2.0). Samples were 
sealed into aluminum pans and heated at a rate of 10 ºC 
min-1, under nitrogen atmosphere. 
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Forced degradation and stability studies   
 
For forced degradation, aliquots of NAR-NGE-NPs were 
transferred to a 1 cm quartz cell (triplicate) and exposed 
in a mirror chamber (100x18x17cm), horizontally 
positioned in order to have the maximum exposure area, 
under the direct incidence of UV-C radiation (Light 
Express lamp LE UV (254 nm/ 30 W). The temperature 
was controlled in the chamber at around 25 ºC. Samples 
were exposed from 1 to 120 hours. After the period in the 
chamber, the samples were analyzed by HPLC under the 
conditions described above. A control sample was 
wrapped in foil and introduced into the chamber for the 
same time intervals. In stability studies, NAR-NGE-NPs 
were stored at room temperature (25 ºC ± 3 ºC), 
refrigerator temperature (5 ºC - 8 ºC), 40 °C and 60 °C for 
60 days. Aliquots were withdrawn at scheduled times and 
analyzed in terms of macroscopic analysis, average 
concentration of both flavonoids, pH and particle size.  
 
Photodegradation kinetics of nanoparticles containing 
naringin and naringenin  
 
The samples were prepared as described in the forced 
degradation study. The degradation order was determined 
by plotting the graph of concentration versus time (zero 
order), logarithm of concentration versus time (first order) 
and inverse concentration versus time (second order). 
Degradation rate constant (k) and t1/2 were calculated after 




NAR and NGE were dissolved in dimethyl sulfoxide 
(DMSO) at a final concentration of 2.0 µg mL-1 of each 
flavonoid. According to the microdilution method 
published by the Clinical and Laboratory Standards 
Institute [18], the MIC of NAR and NGE were determined 
in Mueller–Hinton broth (Difco) against standard ATCC 
(American type culture collection) and isolated (clinical 
isolate and environment isolate) cultures. The following 
bacteria were used: Enterococcus faecalis (ATCC 
29212), Streptococcus sp, Listeria monocytogenes 
(ATCC 7644), Klebsiella pneumonia (ATCC  700603), 
Escherichia coli (ATCC  25922), Shigella flexneri 
(ATCC 12022323A), Salmonella enteritidis, Providencia  
rettgeri (ATCC 2994), Proteus mirabilis (ATCC 25933), 
Morganella morganii (ATCC 8019), Enterobacter 
aerogenes (ATCC 13048), Enterococcus faecium (ATCC 
6569), Acinetobacter baumannii (ATCC 19606), 
Staphylococcus epidermidis (ATCC 35985), 
Paenibacillus larvae (ATCC 9535), Paenibacillus 
borealis, Paenibacillus thianinolyticus, Paenibacillus 
gluconolupticus, Paenibacillus seginolipticus, 
Paenibacillus pabuli, Paenibacillus apiarus, 
Paenibacillus azotofixans, Paenibacillus validus, 






Data were analyzed by one-way ANOVA with the post-
hoc Tukey test. A value of p<0.05 was considered to be 
statistically significant. 
 
Results and Discussion 
 
Determination of solvent 
 
The characteristics of the NPs depend on various 
manufacturing parameters as polymer, organic solvents, 
type and concentration of stabilizer. Thus, the choice of 
the solvent is critical for the success of the method. 
Several parameters should be considered when choosing 
a solvent for making NPs, like physical properties of the 
solvents, ability to dissolve the polymer, drug, and 
toxicity since there will always be trace amounts of 
solvent in the final formulation [19]. Some authors report 
that the physical properties of the organic solvents 
strongly influence the NPs preparations and the particle 
size, since particle formation depends on interfacial 
tension, viscosity of the solvent, solution dielectric 
constant and solubility of the monomer/polymer [20-22]. 
For each solvent and mixture of solvents, NAR-NGE-NPs 
were prepared aiming at NPs with desired particle size 
(<200 nm), PdI (<0.2) and large zeta-potential. Table 1 
shows the effect of different solvents on the particle sizes, 
PdI and zeta-potential of NAR-NGE-NPs. Two different 
polymers were tested maintaining the same 
concentrations of the other constituents of formulations. 
The viscosity of the oil phase, containing the solvent, is 
an important factor in the preparation of NPs [23]. The 
size of NPs depends on the oil phase viscosity; the lower 
the viscosity, the smaller the mean diameter [24]. After 
preparation, the particle size and PdI were less than 200 
nm and 0.2, respectively, except batch 4, which was 
nanometric but larger particles were formed. The smallest 
particles were obtained using ethanol and ethanol: acetone 
(1:1) (Batch 1, 6 and 8). These three batches were stored 
at room temperature (25 ºC ± 3 ºC) and monitored to 
observe possible changes in color, appearance of 
precipitates or sedimentation. After 3 weeks, Batches 6 
and 8 changed color and some sedimentation was visible. 
After that, Batch 1 was selected for characterization and 
stability studies. Likewise, Galindo-Rodriguez [25] 
reported a study with five different solvents: ethanol, 
acetone, DMSO, isopropyl alcohol and ethyl lactate using 
methacrylic acid copolymer. Ethanol showed the smallest 
particle size (79 nm), followed by DMSO (97 nm), 
isopropyl alcohol (101 nm), acetone (146 nm) and ethyl 
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Table 1. Effect of various solvents and two polymers on particle size, PdI and zeta-potential. 
Batch Solvent and proportions Particle size (nm) PdI Zeta-potential (mV) 
Eudragit® L 100 
1 EtOH  121.0 0.096 -16.60 
2 EtOH: Isopropanol (1:1)  145.8 0.151 -21.90 
3 EtOH: Isopropanol (2:1)  106.6 0.186 -12.80 
4 EtOH: THF (1:1)  230.1 0.269 -26.23 
5 EtOH: THF (2:1)  121.3 0,025 -10.90 
6 EtOH: acetone (1:1)  89.3 0.099 -16.16 
7 EtOH: acetone (2:1)  129.5 0.102 -15.90 
Eudragit® S 100 
8 EtOH  99.61 0.095 -9.40 
EtOH – Ethanol; THF – Tetrahydrofuran 
. 
Characterization of optimal suspension of nanoparticles 
 
Figure 1 shows the chromatograms containing NAR (1c), 
NGE (1d), NAR-NGE-NPs (1a and 1b) and excipients 
(1e). A simple, sensitive, precise and linear method by 
HPLC was established for simultaneous determination 
and quantification of NAR and NGE in polymeric NPs. 
The method results in excellent separation in less than 8 
min, with a peak purity and the excipients did not interfere 
in quantification [15].  
The method was validated in compliance with guidelines, 
and was found to be linear in the 1–40 μg mL-1 
concentration range for both NAR and NGE (r > 0.99). 
Repeatability was determined at three concentration 
levels, obtaining an RSD (%) <0.9%, and the accuracy of 
the method was >98% [15]. 
 
 
Figure 1. The HPLC chromatograms of nanoparticles of  
naringin (a), naringenin (b),  naringin (c) and naringenin 
solutions (d) and excipients (e). 
 
NAR-NGE-NPs were prepared by a well-reported 
interfacial deposition of pre-formed polymer method. 
This method is a simple, reproducible process to prepare 
nanocapsules [26]. Ethanol was the best solvent for this 
study; the visual appearance of the suspension was free of 
aggregates and displayed the Tyndall effect. Particle size 
has a crucial impact on the in vivo fate of the particulate 
drug delivery system and size control is very important 
for drug carriers [27]. The size distribution of NAR-NGE-
NPs demonstrated a narrow distribution and the PdI lower 
than 0.1 was identified. The small PdI values indicated a 





The particle size of the formulation without flavonoids 
was 111.60 nm (PdI = 0.159), demonstrating that the 
addition of NAR, and NGE in the formulations did not 
affect the mean diameter. 
No significant (p>0.05) variation was verified when 
comparing the particle size of NAR-NGE-NPs and 
control NPs. These values are in agreement with the 
particle size observed for nanocapsules prepared using the 
same method [26]. 
Zeta-potential values are indicators of surface charge, 
which determines particle stability in dispersion. No 
significant (p>0.05) variation was observed when 
comparing the zeta-potential of NAR-NGE-NPs (-16.60 ± 
0.08 mV) and control-NPs (-19.70 ± 0.03 mV). All 
formulations were negatively charged with a zeta-
potential because of the terminal carboxyl groups of the 
anionic polymer Eudragit® L100. The total content in the 
suspension was 92.15 ± 0.79 % and 90.34 ± 0.84 for NAR 
and NGE, respectively. High encapsulation efficiencies 
were found for NAR (80.90%) and NGE (81.34%). The 
low viscosity (similar to water) of NAR-NGE-NPs was 
found to be 1.44 Cp. The viscosity similar to water 
demonstrated that the NPs did not influence the viscosity 
of the suspension [23]. 
 
Transmission electron microscopy  
 
TEM is a qualitative method used to study the structural  
aspects of materials [28]. The morphological 
characteristics of NAR-NGE-NPs and control NPs were 
investigated. The NPs prepared with Eudragit® L100 




Fig 2. TEM images of NAR-NGE-NPs (500,000 x) and control 
NPs (300,000 x).  
 
 





IR was performed by order to characterize the interactions 
between the polymer Eudragit® L100 and NAR-NGE-
NPs (Figure 3). The spectra of NAR and NGE (3a and 3b) 
showed their characteristic bands [29] and spectra of 
Eudragit® L 100 (3c) showed bands of the C=O vibrations 
of the carboxylic acid groups at 1,700 cm-1. 
A band detected between 2,500-3,500 cm-1 and 2,900–
3,000 cm-1 can be attributed to the associated OH groups 
and CHx vibrations, respectively [13]. The formation of 
the complex between NAR and NGE with Eudragit® L100 
was confirmed by IR analyses, because no new chemical 
bond was formed after preparing the formulation and the 
results confirmed that the flavonoids are physically 
dispersed in the polymer Eudragit® L100. 
 
 
Figure 3. IR spectra of NAR (a), NGE (b), Eudragit® L 100 (c) 
and NAR-NGE-NPs (d). 
  
Differential scanning calorimetry 
 
The DSC profile of NAR, NGE, control-NPs, NAR-NGE-
NPs stored at 60 ºC and at room temperature (25 ºC ± 3 
ºC) are shown in Figure 4. The DSC profile of NAR (4a) 
did not show a defined melting point, this may be 
occurring because NAR is an amorphous structure and 
does not have a melting point [30]. For NGE the fusion 
temperature was 252.61 °C. This shows an endothermal 
event which is represented by descending signals and the 
result is expressed by a negative value of the differential 
signal, corroborating data from the literature [9, 31-33].  
In Figures 4c, 4d and 4e, the thermograms presented 
melting peaks at 40-43ºC, including the control NPs. 
Based on the melting points of the components, we can 
suggest that sorbitan monostearate that has a melting point 
of around 60 °C melted during the storage at 60ºC and was 
responsible for the degradation of the nanostructures at 
this temperature. The shift of the melting point can be 
attributed to the nano size and presence of polymer, oil 
and surfactant in the structure. Absence of new peaks 
suggested that no chemical interactions occurred between 
Eudragit and the flavonoids and confirmed that both 
flavonoids were well encapsulated in the polymeric 
matrices, as previously shown by the techniques TEM 
(Figure 2) and IF analyses (Figure 3). 
 
 
Figure 4. Heating curve obtained by DSC from NAR (4a), NGE 
(4b), control-NPs (4c), NAR-NGE-NPs stored at 60 ºC (4d) and 
at room temperature (25 ºC ± 3 ºC) (4e). 
 
Forced degradation and stability studies   
 
Photodegradation is an important indicator of chemical 
stability. UV-C radiation has high energy, and it can be 
the cause of many oxidation reactions or breakage of 
weak chemical bonds. These phenomena are energy-
related and, thus, are preceded by photons with specified 
wavelength [34]. In forced degradation, the degradation 
profile caused by UV-C revealed that NAR degraded 12% 
and NGE about 6% in 76 hours (Figure 5). Comparing the 
results, when NAR and NGE were not encapsulated, in 48 
hours, NAR degraded 50% and NGE about 60%.  The 
polymer matrix of NPs can contribute to the improved 
stability by NAR and NGE.  A similar study on structural 
stability of coenzyme Q10 loaded within poly (methyl 
methacrylate) showed that both UV induced drug 
inactivation were effectively hindered when the drug was 
encapsulated within the polymer nanoparticles [35]. 
 
 
Figure 5. Profile of degradation by UV-C 
 
Nanocapsule composition, preparation method and 
storage conditions may affect the stability of 
nanoencapsulated systems [36]. For the stability studies, 
all formulations were stable as colloidal suspensions 
without visible creaming, sedimentation, precipitates, 
flocculation or phase separation. NAR-NGE-NPs stored 
at room temperature and freezer and control-NPs retained 
the white color. Formulations subjected to higher 
temperatures, 40 °C and 60 °C, had a slight change in 
color from white to light yellow. The total content of NAR 
and NGE in NPs during stability studies is shown in 
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Figure 6a and 6b. NGE-NPs was more stable than NAR-
NPs. NPs were able to confer protection against the NAR 
and NGE degradation, and it became evident that room 
temperature (25 ºC ± 3 ºC) was the most suitable for 
maintaining NPs stability. 
 
 
Figure 6. Monitoring NAR-NGE-NPs concentration (a) and (b), monitoring pH of the suspensions (c) and monitoring particle size of 
NAR-NGE-NPs (d). 
 
The monitored pH of the suspensions provides an 
important indicator of stability. In general, the pH values 
of nanocapsule dispersions fall within a range of 3.0–7.5 
when produced by nanoprecipitation [36]. This acid 
character of the suspensions can be explained by the 
presence of terminal carboxyl groups of the anionic 
polymer chains [13]. The pH of NAR-NGE-NPs (Figure 
6c) and control-NPs remained acid and, when analyzed 
statistically by ANOVA and Tukey test, showed that there 
was a change only when exposed to a temperature of        
60 °C. The decrease of pH may be due to partial 
degradation of Eudragit® L100, oxidation of any 
constituent or diffusion of the NAR or NGE formulation 
of the nanocapsules to the aqueous phase. Another 
possibility may be linked to sorbitan monostearate, which 
has a melting point of around 60 °C. However, no sign of 
physical-chemical instability were observed in 
formulations. The data on the monitoring of the particle 
size of NAR-NGE-NPs during 60 days are represented in 
Figure 6d. When analyzed statistically by ANOVA and 
Tukey, the values showed that there was a change only 
when exposed to a temperature of 60 °C, suggesting that 
the melt of sorbitan monostearate occurred within the core 
of NPs. Pohlmann and collaborators [37] prepared a 
different NPs formulation: the NPs were composed only 
of the polymer, omitting the sorbitan monostearate. For 
NPs, the sorbitan monostearate would act as an impurity 
affecting the crystallinity of the polymer. And there are  
others sources of nanoparticle instability, the aggregation, 
Ostwald ripening and recrystallization, may lead to 
forming large particles [38]. Ostwald ripening is the effect 
by which small particles are essentially consumed by 
large particles during the growth process, since the small 
particles have a higher solubility than the large particles 
[39]. 
Kinetics of photodegradation of nanoparticles 
 
The kinetics of photodegradation of NAR-NGE-NPs was 
calculated by the concentration of NAR and NGE within 
time. The coefficient that best represents 
photodegradation kinetics for NAR was zero order 
kinetics (r=0.9960), demonstrating that the reaction 
velocity was independent of the active concentration, with 
k of 0.03 µg/hour and t1/2 was 166.67 hour. NGE 
presented a second order kinetics (r= 0.9718), the reaction 
rate depends on two reagents; the value found for k found 




NGE did not present any inhibitory effect over the 
different strains and the presence of glycosides in NAR 
did not enhance antimicrobial activity. This result agrees 
with that reported by Céliz and collaborators [40], who 
studied the antimicrobial activity of NAR, NGE and 
prunin at a concentration of 0.25 mM. In another study, 
NGE was evaluated for the capacity to reduce the 
production of quorum sensing-controlled factors in the 
opportunistic pathogen Pseudomonas aeruginosa. The 
authors found a significant reduction of the production of 
pyocyanin and elastase in P. aeruginosa without affecting 
bacterial growth. The authors emphasized a role as 
inhibitors of the virulence of pathogenic bacteria by 




In this study, novel NAR-NGE-NPs were successfully 
developed by a nanoprecipitation technique, using 
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Eudragit® L100 as polymer and ethanol as solvent. A 
formulation appeared macroscopically homogeneous, and 
the nanometric size had a narrow distribution. IR analyses 
confirmed the structure of NAR-NGE-NPs and 
demonstrated the formation of a complex between NAR 
and NGE with Eudragit® L100. The NAR-NGE-NPs 
presented as spherical and regular shaped in the TEM 
images. Study by UV-C, NAR-NGE-NPs improved the 
photostability and conferred protection against the NAR 
and NGE degradation. Stability studies of NAR-NGE-
NPs demonstrated that only the suspension stored at 60 ºC 
did not show good stability. MIC of NAR and NGE were 
assessed and they did not show antimicrobial activity. 
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